Jogin Desai
@jogin_desai
Followers
396
Following
606
Media
11
Statuses
647
Founder CEO : Eyestem Co-founder: Ignite Life Science Foundation Partner : Social Venture Partners, Bangalore Co-founder: Centre for Eye Genetics/Research
Bengaluru South, India
Joined June 2016
A biotech venture needs 3 key elements - A passionate/aligned team - An innovative solution for a large global problem - Patient investors who can see the forest for the trees We are lucky to have all 3. Hope to use this momentum to make a difference in patient lives worldwide.
Delighted to announce our fund raise by existing investors and one major external investor. This funding enables us to complete our India phase 2 trial, file for the US IND and invest in follow on programs for incurable diseases https://t.co/EnPNWU7Q7g
0
1
7
RPE cell suspension therapy is at a key breakout moment. Independent programs, pursuing a different path to the same goal, have reported out consistent results. Vision recovery for a disease where one loses vision over time is very encouraging. Look forward to sharing our results
Our CEO @jogin_desai will share trial results for Eyecyte-RPE™ at the Greater Bay Cell & Gene Therapy Forum on September 25/26 in Guangzhou. With 14.8 letter vision gain in 8 pts at 6 months with no SAEs, Eyestem is excited to begin Ph 2 trials in India this year/US next year.
0
0
2
Delighted to share the story and science behind @EyestemResearch . Thanks @Arundathi_Ram and @CNBCTV18News for the opportunity
.@EyestemResearch has raised $10M in an oversubscribed round to advance its retinal cell therapy, EyeCyte-RPE The Bengaluru- and Delaware-based biotech will use the funds for Phase 2 trials in India and a U.S. IND filing @Arundathi_Ram decodes the firm’s agenda with @jogin_desai
1
0
6
It is great to see the cell suspension approach being validated now through three independent projects by three fantastic teams. Reaffirms the solidity of the science @EyestemResearch
Congrats to Astellas for joining Lineage and Eyestem and showing that a suspension of lab-grown RPE cells can generate promising clinical outcomes in dryAMD patients. $LCTX
0
1
7
Feels surreal achieving a milestone that we have been dreaming of for the past 5 years! The trial demonstrated meaningful vision improvement (15.8 letters for 6 patients with poor vision in 6 months)while having no Serious Adverse Events. Onward to Ph 2! . https://t.co/xG5ncj4yTY
expresshealthcare.in
The trial evaluates the safety and efficacy of Eyecyte-RPE in patients with geographic atrophy secondary to dry age-related macular degeneration
3
4
21
Thank you @Bios4Action and the entire @lvpei ecosystem for your constant support day day one. Wonderful story by @TheKenWeb
@ns123abc Our bet? Not just hope—execution. With partners like @EyestemResearch , we’re treating blindness once thought incurable. Add generative bio (AlphaFold++) and in silico trials via @cognitivecare_ and we’re 10x’ing care, cutting costs by 90%. DeepMind’s 10-year claim? Feels less
0
0
4
Thank you @Singh10Seema in covering the journey of @EyestemResearch with such eloquence and clarity. Helped us re-live all our special moments from day one !
One of the three companies globally to show cell therapy results for dry AMD, an eye disorder affecting nearly 200 million globally, Bengaluru’s Eyestem is also eyeing a disruptive price. My story today: https://t.co/JxPTDEUqwu
0
1
7
Our phase one trial for severe #DryAMD was (is!) supposed to look at product safety but the early efficacy indicators are truly unexpected. This is welcome news not just for us but for millions of patients. Onwards for phase 2 in India/US. https://t.co/7jMe9pbhie
economictimes.indiatimes.com
Eyestem will be presenting its data at the ARVO 2025 Annual Meeting as well as the 10th Retinal Cell and Gene Therapy Innovation Summit in early May.
1
1
5
All 9 injections for phase 1 done !. So far, we have shown an average 14.9 letter improvement in vision for 6 patients over 3-6 months, anatomical correlations and no SAEs. Improvement in the quality of life of patients has been equally impressive.Look forward to Ph 2 in India/US
Delighted to announce interim results for our phase 1 to treat Geographic Atrophy No Serious Adverse Events reported Average improvement of 14.9 letters in ETDRS over 3-6 m Anatomical changes identified in almost all pts at 3 months Will explore further in Ph 2 in India/US
0
1
10
Much awaited publication for this remarkable collaborative effort of @TataMemorial, @iitbombay, @ActImmuno in bringing affordable and effective CAR-T cell therapy to our patients.
1
1
6
The stories about how legally blind patients are getting impacted due to this treatment is one of the most fulfilling experiences of my life A word of caution esp for patients. This Rx is experimental as of now and a long road still to market. https://t.co/1uKmTNGxBY
linkedin.com
The stories about how legally blind patients are getting impacted due to this treatment has been one of the most fulfilling experiences of my life. - Patient XXXX used to work in a small shop and...
Delighted to announce interim results for our FIH trial for treatment of GA 1. No SAEs and minimal TEAEs, 2. Five out of Six patients had a improvement in vision (3-31 letters). 3. Noticeable decrease in RPE/PR defect areas 4. Structural changes in OCT https://t.co/KdioXxskV3)
2
1
8
This is a great initiative by the Indian govt. We all want to live in a world where this is not needed but until the science publishing world reforms, someone has to do something !
science.org
Deal allows scholars to read paywalled articles for free and will cover open-access fees
0
0
8
This is fantastic news and a big shoutout to the @wockhardt teams who made this possible . A big win for patients in India and abroad !
14 years of R&D and trials, around 500 crores rupees ..... India's first indigenous antibiotic Nafithromycin. https://t.co/PzDdraVJt5
0
2
6
A therapy is only as useful as the surgeon's comfort with delivering it safely and effectively. Figuring out pain points/addressing them is key to ultimate market adoption. To quote Da Vinci "Simplicity is the ultimate sophistication"! One step closer @BattuRajani @RajarshiPal16
Stoked to announce patent filing for our customized Sub-retinal injection technique to safely deliver Eyecyte-RPE in the area of interest for Geographic Atrophy .The invention harnesses readily available instruments and integrates them in a counter intuitive yet effective way!
0
2
9
Meet Shravanti Rampalli This month's 'Meet the IgniteLSF Team' introduces @shravrampalli Rampalli, CEO. @swami2m Subramaniam continues to be with us at Ignite in his new role of Member of the Scientific Advisory Board.” https://t.co/YsMAny3GK0
linkedin.com
Meet Shravanti Rampalli This month's 'Meet the IgniteLSF Team' introduces Shravanti Rampalli, CEO. Welcoming her to Ignite Life Science Foundation, Dr Pankaj Chandra, Chair of the Ignite Board said:...
7
2
33
The first few patients are always the most critical. One gets a fundamental understanding about the safety profile, surgical delivery and the cell interaction with the diseased retina. The first principles knowledge has enhanced our confidence for this product to transform lives
Delighted to announce approval from our Drug Safety Monitoring Board (DSMB) to move forward with the second cohort of patients for our phase one trial to treat Geographic Atrophy secondary to Dry AMD
1
2
8
BIO-PHARMA: In a groundbreaking development for #ophthalmology research, @EyestemResearch has completed the first set of three patient injections for its RPE suspension therapy for Dry age-related macular degeneration. Click to read: https://t.co/wwx1A8gg2V via #BiovoiceNews
0
3
7
One step closer to market! As part of its ongoing clinical trials, @EyestemResearch, a CCAMP supported & incubated startup has completed the first round of patient injections for treatment of dry age-related macular degeneration (AMD)! 🔗 https://t.co/yh8Z7K6LJz… AMD is a
0
2
4
Indeed. Exciting times for all of us at @EyestemResearch
So far so good, next cohort looks closer! Exciting times! https://t.co/YcAXtCYcmo
@jogin_desai @BattuRajani @CCAMP_India @Taslimarif @BIRAC_2012
0
0
1